Epilepsy News and Research

Latest Epilepsy News and Research

Vertex announces modification of telaprevir and VX-222 combination Phase 2 trial for treatment of HCV

Vertex Pharmaceuticals Incorporated today announced a modification of its Phase 2 clinical trial evaluating 12-week, response-guided regimens of its lead investigational hepatitis C virus (HCV) protease inhibitor, telaprevir, in combination with its lead investigational HCV polymerase inhibitor, VX-222.

22 Dec 2010

$Emory University study reaffirms benefits of VNS Therapy System for refractory epilepsy$

Emory University study reaffirms benefits of VNS Therapy System for refractory epilepsy

Cyberonics, Inc. announced today that the VNS Therapy System, the only FDA-approved implantable medical device for the treatment of refractory epilepsy, was featured in 22 poster presentations and in the Plenary II session on neurostimulation at the annual American Epilepsy Society Meeting that took place recently in San Antonio, Texas.

22 Dec 2010

Anavex files regulatory submission in Germany for ANAVEX 2-73 Phase I trial in Alzheimer's disease

Anavex Life Sciences Corp. announced today that it has filed the regulatory submission for ANAVEX 2-73 with the German Health Authority, BfArM, and the local Ethics Committee of Saxony to begin clinical studies for ANAVEX 2-73, its lead compound for the treatment of Alzheimer's disease.

21 Dec 2010

VistaGen reports successful completion of AV-101 Phase 1 safety study for neuropathic pain

VistaGen Therapeutics, Inc., a stem cell technology company focused on drug discovery and development, today announced the successful completion of its initial Phase 1 safety study of AV-101, the Company's novel orally available prodrug candidate for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects approximately 1.8 million people in the U.S.

20 Dec 2010

Proteins that unlock the mystery of over 100 brain diseases

An Anglo-American team of researchers have made a medical breakthrough after identifying a large collection of nerve proteins that are involved in around 130 brain diseases including Alzheimer’s and autism.

20 Dec 2010

Icagen, Pfizer commence Nav1.7 Phase I clinical studies for pain and related disorders

Icagen, Inc. today provided an update on its sodium channel program for pain and related disorders, which is being conducted in collaboration with Pfizer. As previously reported, the companies recently selected a candidate compound to advance into further clinical studies. Dosing of this candidate compound has now been initiated in a Phase I study in healthy volunteers.

20 Dec 2010

Natus Medical anticipates revenue of $247M to $250M for full year 2011

Natus Medical Incorporated today announced its financial guidance for the first quarter and full year 2011.

20 Dec 2010

Completely fearless woman stirs scientific interest

It has been known since the 1930s that when a certain part of monkeys’ brains were removed, the animals became fearless. Now similar effects are being seen in humans according to a study in the journal Current Biology. Justin Feinstein, the study’s lead author and a clinical neuropsychologist at the University of Iowa said, “There’s not very many humans with this sort of brain damage… Luckily for us, we had access to a patient, SM, and we studied her different fear behaviours and we read her personal diaries.”

19 Dec 2010

Second brain death exam impacts organ donation rates

Requiring a second exam on a person who is considered brain dead may be unnecessary, according to a study on the impact of a second brain death exam on organ donation rates. The research is published in the December 15, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology.

16 Dec 2010

Zenobia, Lundbeck enter research collaboration for LRRK2 Parkinson's disease target

Zenobia Therapeutics, Inc. the leader in fragment-based lead discovery for CNS diseases, announced today a research collaboration with H. Lundbeck A/S utilizing Zenobia's expertise in protein expression and x-ray crystallography for the Parkinson's disease target, LRRK2. Under the agreement, Zenobia will continue to use its capabilities in fragment-based lead discovery (FBLD) to advance its internal LRRK2 drug discovery program independently of Lundbeck.

16 Dec 2010

Researchers examine expression of toxic mRNA in patients with Fragile X Tremor Ataxia Syndrome

Expression of a toxic RNA that leads to Fragile X Tremor Ataxia Syndrome is modifiable by genetic or pharmacologic means, according to new research from U-M Medical School scientists.

15 Dec 2010

DBS targets same class of neuronal cells that respond to physical exercise and drug Prozac

Shooting steady pulses of electricity through slender electrodes into a brain area that controls complex behaviors has proven to be effective against several therapeutically stubborn neurological and neuropsychiatric disorders. Now, a new study has found that this technique, called deep brain stimulation (DBS), targets the same class of neuronal cells that are known to respond to physical exercise and drugs such as Prozac.

15 Dec 2010

American Epilepsy Society recognizes neuroscientist for basic science advances

Douglas A. Coulter, Ph.D., a neuroscientist at The Children's Hospital of Philadelphia, received the 2010 Epilepsy Research Recognition Award for Basic Science from the American Epilepsy Society. The Society honored Dr. Coulter's pioneering contributions to epilepsy research on Monday, Dec. 6 at its Annual Meeting in San Antonio.

14 Dec 2010

Lack of strong molecular 'glue' allows tumour cells to break away and spread

A remarkable discovery into how tumour cells invade normal tissue should lead to vital diagnostic tools and help develop strategies to stop the spread of cancer cells. A new study by scientists at the Montreal Neurological Institute and Hospital of McGill University reveals that the surface of aggressive tumour cells lack the strong molecular 'glue' responsible for binding normal cells together.

14 Dec 2010

Study finds expression of toxic RNA that leads to Fragile X Tremor Ataxia Syndrome modifiable

Expression of a toxic RNA that leads to Fragile X Tremor Ataxia Syndrome is modifiable by genetic or pharmacologic means, according to new research from U-M Medical School scientists.

14 Dec 2010

Majority of brain tumor patients use alternative therapies

Many people with incurable brain tumors use alternative therapies, such as taking vitamins and homeopathy, in addition to their conventional treatments, according to a study published in the December 14, 2010, print issue of Neurology®, the medical journal of the American Academy of Neurology.

13 Dec 2010

Dogs help understand primary ciliary dyskinesia

A dog is mankind's best friend : the old saying has once again been borne out through a medical discovery concerning the genetic origins of primary ciliary dyskinesia (PCD). In using dogs as a research model in the framework of the European LUPA project, a team from the University of Liège's GIGA-Research Unit has been able to bring to light new mutations in a specific gene responsible for the development of the disease in human beings.

9 Dec 2010

New finding could help identify individuals with abnormal brain function

Mayo Clinic researchers found that the part of the brain generating seizures in individuals with epilepsy is functionally isolated from surrounding brain regions. The researchers hope this finding could be a clinical biomarker to help identify individuals with abnormal brain function.

9 Dec 2010

Low-dose diazepam with NS-398 combination has twice the neuroprotective effect of NS-398 alone

Status epilepticus, prolonged seizures, can lead to significant neurological deficits and, rarely, even death. The anticonvulsant diazepam, a first line therapy for the condition, is neuroprotective when administered in high doses within two hours from seizure onset. Researchers at the 64th AES Annual Meeting now report that the combination of low-dose diazepam and NS-398, a COX-2 inhibitor, has twice the neuroprotective effect of NS-398 alone.

8 Dec 2010

AHNPs may serve as effective treatment for epilepsy and other disorders with altered neuronal circuitry

Epilepsy research is reaching beyond improving the means for quelling symptoms to the exploration of potential modalities for correcting or reversing alterations in neural function that underlay some forms of the disorder.

8 Dec 2010

Epilepsy News and Research

Latest Epilepsy News and Research

Vertex announces modification of telaprevir and VX-222 combination Phase 2 trial for treatment of HCV

Emory University study reaffirms benefits of VNS Therapy System for refractory epilepsy

Anavex files regulatory submission in Germany for ANAVEX 2-73 Phase I trial in Alzheimer's disease

VistaGen reports successful completion of AV-101 Phase 1 safety study for neuropathic pain

Proteins that unlock the mystery of over 100 brain diseases

Icagen, Pfizer commence Nav1.7 Phase I clinical studies for pain and related disorders

Natus Medical anticipates revenue of $247M to $250M for full year 2011

Completely fearless woman stirs scientific interest

Second brain death exam impacts organ donation rates

Zenobia, Lundbeck enter research collaboration for LRRK2 Parkinson's disease target

Researchers examine expression of toxic mRNA in patients with Fragile X Tremor Ataxia Syndrome

DBS targets same class of neuronal cells that respond to physical exercise and drug Prozac

American Epilepsy Society recognizes neuroscientist for basic science advances

Lack of strong molecular 'glue' allows tumour cells to break away and spread

Study finds expression of toxic RNA that leads to Fragile X Tremor Ataxia Syndrome modifiable

Majority of brain tumor patients use alternative therapies

Dogs help understand primary ciliary dyskinesia

New finding could help identify individuals with abnormal brain function

Low-dose diazepam with NS-398 combination has twice the neuroprotective effect of NS-398 alone

AHNPs may serve as effective treatment for epilepsy and other disorders with altered neuronal circuitry

Fast Facts - Everything there is to know about epilepsy eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Epilepsy News and Research

Latest Epilepsy News and Research

Fast Facts - Everything there is to know about epilepsy eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in